RevMed's Rasonque nets $198M; Madrigal sued over Rezdiffra data; Rezera eyes $181M IPO; ANI bids $560M for Egetis; Cloudbreak ...
Ellipsis, which uses voice AI to screen and chat with patients, bought Kouper Health, which carries out ...
Caldera Therapeutics is going back to its existing partner Qyuns Therapeutics for a IL-17xTL1A bispecific antibody, while ...
Oxford spinout Alethio raises $90M Series A co-led by Sofinnova and RA Capital to take ET antibody ATX-011 into the clinic.
Kamau Therapeutics shares early data on nula-cel 2.0 for sickle cell disease; 3 patients show no pain crises or transfusion ...
Sanofi drops SAR448272, a STAT6 degrader developed with Nurix Therapeutics, after Phase 1 discontinuation. Nurix shares fell ...
Biotech pessimism about China more than doubles in Q3 BPSI, making it biopharma’s No. 2 worry, while Big Pharma stays net ...
CVS Health (Aetna, Caremark, Oak Street) and CVS Pharmacy. CEO David Joyner leads health unit; Prem Shah leads pharmacy.
J&J’s trispecific ramantamig shows 100% ORR in newly diagnosed myeloma, Tibsovo hits EFS in frontline AML, Calquence combo ...
Endpoints’ Drew Armstrong and Max Bayer join policy expert Nick Shipley live Wednesday to break down what the US midterms ...
Spyre drops SPY072 for rheumatic diseases after SKYWAY trial failures; Ideaya halts darovasertib UM trial; United ...
Pfizer CEO Albert Bourla says Trump’s MFN pricing deals will hold through the end of the term, even if Democrats win Congress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results